Incorporation of crizotinib into the NCCN guidelines

J Natl Compr Canc Netw. 2011 Dec;9(12):1328-30. doi: 10.6004/jnccn.2011.0113.
No abstract available

Publication types

  • Evaluation Study

MeSH terms

  • Anaplastic Lymphoma Kinase
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / diagnosis
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / genetics
  • Clinical Trials as Topic
  • Crizotinib
  • Humans
  • Lung Neoplasms / diagnosis
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics
  • Medical Oncology / legislation & jurisprudence*
  • Medical Oncology / organization & administration
  • Medical Oncology / trends
  • Molecular Diagnostic Techniques
  • Mutation / physiology
  • Practice Guidelines as Topic*
  • Prognosis
  • Protein Kinase Inhibitors / administration & dosage
  • Pyrazoles / administration & dosage*
  • Pyridines / administration & dosage*
  • Receptor Protein-Tyrosine Kinases / genetics
  • Societies, Medical / legislation & jurisprudence

Substances

  • Protein Kinase Inhibitors
  • Pyrazoles
  • Pyridines
  • Crizotinib
  • Anaplastic Lymphoma Kinase
  • Receptor Protein-Tyrosine Kinases